SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

IM-1617

IMNM·Immunome Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 1
Time to market
IM-1617 is in Phase 1 dose-escalation; assuming successful development, potential approval would be several years away (likely 2029-2031 at the earliest).
Why 3/10
IM-1617 is in Phase 1 with no scheduled data readout or regulatory catalyst in the next 12 months. The stock's next major catalyst is varegacestat's PDUFA date on April 28, 2027, not IM-1617. As an early-stage asset in a multi-program company, IM-1617 alone is unlikely to drive a significant share-price move in the near term.
Actionable Insight NEUTRAL

IM-1617 is an early Phase 1 asset with no publicly announced data readout date. The next major catalyst for Immunome overall is the varegacestat PDUFA decision on April 28, 2027. For IM-1617 specifically, watch for any initial safety/efficacy data from the Phase 1 trial, which could emerge in 2027 at a medical conference or corporate update.

Price Chart

Loading chart...

Executive Summary

IM-1617 is a potential first-in-class antibody-drug conjugate (ADC) targeting an undisclosed receptor tyrosine kinase in advanced solid tumors, developed by Immunome Inc. (NASDAQ: IMNM). It uses Immunome's proprietary topoisomerase I inhibitor payload (HC74). The drug received IND clearance in April 2026 and the first patient was dosed in a Phase 1 first-in-human trial in June 2026. IM-1617 is one of several early-stage ADC candidates in Immunome's pipeline, which is led by varegacestat (desmoid tumors, PDUFA April 28, 2027). As a Phase 1 asset with no near-term binary catalyst, IM-1617 is a small part of the Immunome investment thesis at this stage.

How It Works

IM-1617 is an antibody-drug conjugate (ADC), a type of cancer therapy that works like a guided missile. It consists of an antibody that seeks out and binds to a specific protein (a receptor tyrosine kinase) found on the surface of solid tumor cells, attached to a powerful chemotherapy drug (HC74, a topoisomerase I inhibitor). Once the antibody binds to the cancer cell, the cell absorbs the ADC and releases the chemotherapy payload inside, killing the cancer cell while sparing most healthy tissue.

Trial Status

Phase 1 first-in-human trial initiated; first patient dosed June 11, 2026. The trial is evaluating IM-1617 in patients with advanced solid tumors. No interim data or readout date has been announced.

The Two-Sided Case

▲ Bull Case4
IM-1617 is a potential first-in-class ADC targeting an undisclosed receptor tyrosine kinase with Immunome's proprietary TOP1 inhibitor payload HC74, offering a novel mechanism in solid tumors.
IND clearance was received in April 2026 and first patient dosed in June 2026, showing rapid clinical execution.
Immunome has a strong balance sheet ($461.6M cash, runway into 2028) to fund the Phase 1 trial without near-term dilution risk.
Immunome's broader ADC platform (IM-1021, IM-1617, IM-3050, IM-1340) creates pipeline-in-a-product optionality, with IM-1617 as a key solid tumor candidate.
▼ Bear Case4
IM-1617 is a very early-stage (Phase 1) asset with no efficacy data yet; the vast majority of Phase 1 oncology ADCs fail to advance.
Immunome's lead asset varegacestat is the primary value driver; IM-1617 contributes negligible standalone value to the stock at this stage.
The target (an undisclosed receptor tyrosine kinase) is not disclosed, making it impossible to assess differentiation vs. competing ADCs.
Immunome's Q3 2026 net loss widened to $85.8M and R&D expenses rose 41% YoY, indicating significant cash burn across the pipeline including IM-1617.

Upcoming Catalysts

  • Initial Phase 1 safety/tolerability data from IM-1617 (no date announced; could emerge at a medical conference in 2027)
  • IM-1021 updated data at ASH 2026 (December 14, 2026), not IM-1617 but relevant to Immunome's ADC platform thesis
  • Varegacestat PDUFA target action date (April 28, 2027), Immunome's primary near-term catalyst

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Immunome Inc. 8-K IMNM ·Originating report

Sources · 7

Hover a chip for the title
1 sec.gov2 businesswire.com3 investing.com4 sec.gov5 sec.gov6 msn.com7 seekingalpha.com